Across TCGA pan-cancer cohorts, LINC00710 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC00710 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LINC00710 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC00710 expression acts as an unfavorable survival marker.
CHOL are the cancer types where LINC00710 Mutation most reproducibly stratifies survival.